A Look into Angina Pectoris Drugs Industry……Deep Analysis…..


The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.
The global angina pectoris drugs market size was valued at USD 8.5 Billion in 2016 and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S. dominated angina pectoris drugs market among the seven major countries. The global angina pectoris market is expected to be collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.
To Request Sample Copy of this report, click the link:
Further key findings from the report suggest:
·         The U.S. dominated this space by accounting for more than 33.0% of the market share in 2016 due to increasing incidence of cardiac disorders and presence of key manufacturers in the U.S.
·         The angina pectoris drug market is commercially meaningful, however branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca and Pfizer hold significant market positions
·         Biosimilar development is emerging as a promising market opportunity in angina pectoris therapeutics. Multiple biosimilars have gained approvals in the U.S., European and Indian markets
·         China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform and supportive 12th Five-Year Plan measure, which targets biotechnology as the key development sector
·         Changing regulatory scenario in the U.S. presents favorable environment for disruptive technologies in healthcare. In the EU, the new Clinical Trials Regulation (EU No. 536/2014) will impact clinical trials of Advanced Therapy Medicinal Products. Industry concerns regarding ROIs on novel therapies remains a challenge to drug development.
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work. 
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris. We estimate annual risk of associated non-fatal myocardial infarction (MI) and death at 3% and 1.0-2.0% respectively. The prevalence of angina rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74 and from 0.1- 1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74.
Have any Query? Ask our Experts:
Grand View Research has segmented the global angina pectoris drugs market based on therapeutic class:
Therapeutic Class Outlook (% market share; 2016 - 2022)
·         Beta Blockers
·         Calcium Antagonists
·         Anticoagulants
·         Anti-Platelets
·         Others
o    Nitrates
o    Anti-anginal (Ranolazine)
o    ACE inhibitors
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.



Comments

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

A Look into Smokehouse Industry……Deep Analysis…..

A Look into Shapewear Industry……Deep Analysis…..